Promising cholesterol drugs from Sanofi, Regeneron, Amgen, Pfizer face scrutiny
This article was originally published in Scrip
Questions about future drug approvals are surfacing as Sanofi, Regeneron Pharmaceuticals, Amgen and others chase a potential multi-billion dollar market that improves upon standard cholesterol-lowering medicines and helps millions of people who are difficult to treat.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.